Semper Paratus Acquisition (TVGN) Competitors $1.22 +0.02 (+1.67%) Closing price 04:00 PM EasternExtended Trading$1.22 0.00 (-0.41%) As of 05:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TVGN vs. MLYS, AVDL, PHVS, NRIX, ARDX, ORIC, PRAX, ZYME, LENZ, and CRMDShould you be buying Semper Paratus Acquisition stock or one of its competitors? The main competitors of Semper Paratus Acquisition include Mineralys Therapeutics (MLYS), Avadel Pharmaceuticals (AVDL), Pharvaris (PHVS), Nurix Therapeutics (NRIX), Ardelyx (ARDX), Oric Pharmaceuticals (ORIC), Praxis Precision Medicines (PRAX), Zymeworks (ZYME), LENZ Therapeutics (LENZ), and CorMedix (CRMD). These companies are all part of the "pharmaceutical products" industry. Semper Paratus Acquisition vs. Its Competitors Mineralys Therapeutics Avadel Pharmaceuticals Pharvaris Nurix Therapeutics Ardelyx Oric Pharmaceuticals Praxis Precision Medicines Zymeworks LENZ Therapeutics CorMedix Mineralys Therapeutics (NASDAQ:MLYS) and Semper Paratus Acquisition (NASDAQ:TVGN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings, media sentiment and analyst recommendations. Is MLYS or TVGN more profitable? Semper Paratus Acquisition's return on equity of 0.00% beat Mineralys Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Mineralys TherapeuticsN/A -71.15% -65.71% Semper Paratus Acquisition N/A N/A -934.56% Do analysts prefer MLYS or TVGN? Mineralys Therapeutics currently has a consensus price target of $32.25, suggesting a potential upside of 131.18%. Semper Paratus Acquisition has a consensus price target of $10.00, suggesting a potential upside of 719.67%. Given Semper Paratus Acquisition's stronger consensus rating and higher probable upside, analysts clearly believe Semper Paratus Acquisition is more favorable than Mineralys Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mineralys Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Semper Paratus Acquisition 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to MLYS or TVGN? In the previous week, Mineralys Therapeutics and Mineralys Therapeutics both had 3 articles in the media. Mineralys Therapeutics' average media sentiment score of 0.66 beat Semper Paratus Acquisition's score of 0.62 indicating that Mineralys Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mineralys Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Semper Paratus Acquisition 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, MLYS or TVGN? Mineralys Therapeutics has a beta of -0.3, indicating that its stock price is 130% less volatile than the S&P 500. Comparatively, Semper Paratus Acquisition has a beta of -0.73, indicating that its stock price is 173% less volatile than the S&P 500. Do institutionals and insiders hold more shares of MLYS or TVGN? 84.5% of Mineralys Therapeutics shares are owned by institutional investors. 33.2% of Mineralys Therapeutics shares are owned by company insiders. Comparatively, 73.2% of Semper Paratus Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has higher valuation and earnings, MLYS or TVGN? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMineralys TherapeuticsN/AN/A-$177.81M-$3.73-3.74Semper Paratus AcquisitionN/AN/A-$13.73MN/AN/A SummaryMineralys Therapeutics and Semper Paratus Acquisition tied by winning 5 of the 10 factors compared between the two stocks. Get Semper Paratus Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for TVGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TVGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TVGN vs. The Competition Export to ExcelMetricSemper Paratus AcquisitionMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$224.35M$2.88B$5.46B$8.92BDividend YieldN/A2.44%5.24%4.04%P/E RatioN/A20.8027.0320.12Price / SalesN/A193.35380.1493.64Price / CashN/A41.7026.2128.59Price / Book-13.567.487.995.57Net Income-$13.73M-$55.04M$3.16B$248.40M7 Day PerformanceN/A5.43%3.68%6.02%1 Month Performance-14.69%2.37%2.89%7.67%1 Year Performance74.79%5.53%34.30%20.92% Semper Paratus Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TVGNSemper Paratus Acquisition3.9662 of 5 stars$1.22+1.7%$10.00+719.7%+71.4%$224.35MN/A0.003Positive NewsMLYSMineralys Therapeutics2.1521 of 5 stars$13.53-1.3%$32.25+138.4%+8.8%$893.55MN/A-3.6328AVDLAvadel Pharmaceuticals2.4432 of 5 stars$8.85-3.8%$18.17+105.3%-39.9%$890M$169.12M-32.7870PHVSPharvaris1.7751 of 5 stars$17.60+3.5%$36.20+105.7%+8.1%$888.93MN/A-5.8530Positive NewsGap UpNRIXNurix Therapeutics1.6214 of 5 stars$11.39-2.1%$30.18+164.9%-36.5%$887.38M$54.55M-4.07300Upcoming EarningsARDXArdelyx4.4392 of 5 stars$3.92+6.2%$10.89+177.8%-17.8%$882.85M$333.61M-17.8290ORICOric Pharmaceuticals4.6224 of 5 stars$10.15-1.6%$19.17+88.8%+38.5%$878.66MN/A-5.4380Analyst ForecastPRAXPraxis Precision Medicines2.9514 of 5 stars$42.05-2.2%$92.11+119.1%+15.8%$875.87M$8.55M-3.92110Analyst ForecastZYMEZymeworks2.0787 of 5 stars$12.55+0.6%$21.00+67.3%+47.3%$867.63M$93.38M-8.37460LENZLENZ Therapeutics1.335 of 5 stars$29.31-2.9%$46.60+59.0%+74.4%$849.45MN/A-16.56110CRMDCorMedix2.759 of 5 stars$12.32-1.4%$17.14+39.1%+177.2%$847.81M$43.47M56.0030High Trading Volume Related Companies and Tools Related Companies Mineralys Therapeutics Competitors Avadel Pharmaceuticals Competitors Pharvaris Competitors Nurix Therapeutics Competitors Ardelyx Competitors Oric Pharmaceuticals Competitors Praxis Precision Medicines Competitors Zymeworks Competitors LENZ Therapeutics Competitors CorMedix Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TVGN) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredNobel Prize Material Finally Goes CommercialA Nobel Prize–winning material just got its biggest breakthrough in 30 years. A little-known company has cr...True Market Insiders | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Semper Paratus Acquisition Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Semper Paratus Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
